Li Lu1,2, Shuyu Ye1,2, Rebecca L Scalzo2,3, Jane E B Reusch2,3, Clifford R Greyson1,2, Gregory G Schwartz4,5. 1. Cardiology Section, Denver VA Medical Center, 1055 Clermont St, Mail Code 111B, Denver, CO, 80220, USA. 2. University of Colorado School of Medicine, Aurora, CO, USA. 3. Endocrinology/Metabolism Section, Denver VA Medical Center, Denver, CO, USA. 4. Cardiology Section, Denver VA Medical Center, 1055 Clermont St, Mail Code 111B, Denver, CO, 80220, USA. Gregory.Schwartz@va.gov. 5. University of Colorado School of Medicine, Aurora, CO, USA. Gregory.Schwartz@va.gov.
Abstract
AIMS/HYPOTHESIS: Metformin is the drug most often used to treat type 2 diabetes. Evidence suggests that metformin may reduce mortality of individuals with type 2 diabetes, but the mechanism of such an effect is unknown and outcomes of metformin treatment in people without diabetes have not been determined. If metformin favourably affected mortality of non-diabetic individuals, it might have even broader therapeutic utility. We evaluated the effect of metformin on myocardial energetics and ischaemic ventricular fibrillation (VF) in metabolically normal pigs. METHODS: Domestic farm pigs were treated with metformin (30 mg kg-1 day-1 orally for 2-3 weeks; n = 36) or received no treatment (n = 37). Under anaesthesia, pigs underwent up to 90 min low-flow regional myocardial ischaemia followed by 45 min of reperfusion. Pigs were monitored for arrhythmia, monophasic action potential morphology, haemodynamics and myocardial substrate utilisation, AMP-activated protein kinase (AMPK) phosphorylation activity and ATP concentration. RESULTS: Death due to VF occurred in 12% of pigs treated with metformin compared with 50% of untreated controls (p = 0.03). The anti-fibrillatory effect of metformin was associated with attenuation of action potential shortening in ischaemic myocardium (p = 0.02) and attenuation of the difference in action potential duration between ischaemic and non-ischaemic regions (p < 0.001) compared with untreated controls. Metformin had no effect on myocardial contractile function, oxygen consumption, or glucose or lactate utilisation. During ischaemia, however, metformin treatment amplified the activation of AMPK and preserved ATP concentration in myocardium compared with untreated controls (each p < 0.05). CONCLUSIONS/ INTERPRETATION: Chronic treatment of metabolically normal pigs with metformin at a clinically relevant dose reduces mortality from ischaemic VF. This protection is associated with preservation of myocardial energetics during ischaemia. Maintenance of myocardial ATP concentration during ischaemia is likely to prevent action potential shortening, heterogeneity of repolarisation, and propensity for lethal arrhythmia. The findings suggest that metformin might be protective in non-diabetic individuals with coronary heart disease.
AIMS/HYPOTHESIS: Metformin is the drug most often used to treat type 2 diabetes. Evidence suggests that metformin may reduce mortality of individuals with type 2 diabetes, but the mechanism of such an effect is unknown and outcomes of metformin treatment in people without diabetes have not been determined. If metformin favourably affected mortality of non-diabetic individuals, it might have even broader therapeutic utility. We evaluated the effect of metformin on myocardial energetics and ischaemic ventricular fibrillation (VF) in metabolically normal pigs. METHODS: Domestic farm pigs were treated with metformin (30 mg kg-1 day-1 orally for 2-3 weeks; n = 36) or received no treatment (n = 37). Under anaesthesia, pigs underwent up to 90 min low-flow regional myocardial ischaemia followed by 45 min of reperfusion. Pigs were monitored for arrhythmia, monophasic action potential morphology, haemodynamics and myocardial substrate utilisation, AMP-activated protein kinase (AMPK) phosphorylation activity and ATP concentration. RESULTS:Death due to VF occurred in 12% of pigs treated with metformin compared with 50% of untreated controls (p = 0.03). The anti-fibrillatory effect of metformin was associated with attenuation of action potential shortening in ischaemic myocardium (p = 0.02) and attenuation of the difference in action potential duration between ischaemic and non-ischaemic regions (p < 0.001) compared with untreated controls. Metformin had no effect on myocardial contractile function, oxygen consumption, or glucose or lactate utilisation. During ischaemia, however, metformin treatment amplified the activation of AMPK and preserved ATP concentration in myocardium compared with untreated controls (each p < 0.05). CONCLUSIONS/ INTERPRETATION: Chronic treatment of metabolically normal pigs with metformin at a clinically relevant dose reduces mortality from ischaemic VF. This protection is associated with preservation of myocardial energetics during ischaemia. Maintenance of myocardial ATP concentration during ischaemia is likely to prevent action potential shortening, heterogeneity of repolarisation, and propensity for lethal arrhythmia. The findings suggest that metformin might be protective in non-diabetic individuals with coronary heart disease.
Authors: Talha A Farid; Krishnakumar Nair; Stephéne Massé; Mohammed Ali Azam; Ange Maguy; Patrick F H Lai; Karthikeyan Umapathy; Paul Dorian; Vijay Chauhan; András Varró; Abdul Al-Hesayen; Menashe Waxman; Stanley Nattel; Kumaraswamy Nanthakumar Journal: Circ Res Date: 2011-10-06 Impact factor: 17.367
Authors: Agnes S Kim; Edward J Miller; Tracy M Wright; Ji Li; Dake Qi; Kwame Atsina; Vlad Zaha; Kei Sakamoto; Lawrence H Young Journal: J Mol Cell Cardiol Date: 2011-03-29 Impact factor: 5.000
Authors: David Preiss; Suzanne M Lloyd; Ian Ford; John J McMurray; Rury R Holman; Paul Welsh; Miles Fisher; Chris J Packard; Naveed Sattar Journal: Lancet Diabetes Endocrinol Date: 2013-11-07 Impact factor: 32.069
Authors: Anna Ostropolets; Pierre A Elias; Michael V Reyes; Elain Y Wan; Utpal B Pajvani; George Hripcsak; John P Morrow Journal: Circ Arrhythm Electrophysiol Date: 2021-02-07